Baxter bids general counsel adieu
This article was originally published in The Gray Sheet
Executive Summary
Marla Persky, 48, assumes acting general counsel title in wake of Thomas Sabatino's decision to resign from firm and become Schering-Plough's general counsel, effective April 15. A 16-year Baxter veteran, Persky had been serving as deputy general counsel and managing the law function for the company's renal business, as well as its litigation, regulatory and intercontinental legal teams. Baxter is seeking a permanent replacement for Sabatino, who recently helped craft AdvaMed's code of ethics. The firm continues to work with headhunter Heidrick & Struggles to fill the CEO spot to be vacated by Harry Kraemer (1"The Gray Sheet" Feb. 4, 2004, p. 11)...
You may also be interested in...
Buck Stops With Kraemer: Baxter CEO Resigns To Restore Investor Confidence
A fresh round of restructuring will save Baxter $200 mil.-$300 mil. a year, shore up core business segments and help pave the way for future growth, the firm says
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.